KDR and hepatocellular carcinoma: Among these molecules, VEGF strongly promotes angiogenesis, and in fact, most of the MTAs approved to date for advanced HCC, such as sorafenib, regorafenib, and lenvatinib, target the VEGF/VEGF receptor (VEGFR) angiogenic pathway.